Cartesian Therapeutics
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING2
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Descartes-08 NCT04146051 |
P2 | Active, not recruiting | Myasthenia Gravis, Generalized | 30 | 2026-01-05 (+50 mo) |
| SLE-001 NCT06038474 |
P2 | Active, not recruiting | Systemic Lupus Erythematosus (SLE) | 6 | 2026-12-01 (+13 mo) |
| Decartes-08 NCT06799247 |
P3 | Active, not recruiting | Myasthaenia Gravis | 128 | 2026-12-30 (+8 mo) |
| Descartes-08 NCT07391605 |
P2 | Recruiting | Antisynthetase Syndrome | 60 | 2027-11 |
| Descartes-08 NCT07089121 |
P1/2 | Recruiting | Childhood-onset Systemic Lupus Erythematous; ANCA-Associated Vasculitis (AAV) | 50 | 2027-12 (+12 mo) |